Drugs / IMP3-Mito
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07572864 | Apr 2026 → May 2027 expected | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP3-Mito | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07572864 ↗ |
| Known as | Engineered Mitochondrial Vaccine | “Engineered Mitochondrial Vaccine (IMP3-Mito)” NCT07572864 ↗ |
| Action | Activate | “activate dendritic cells and prime tumor-specific T-cell responses” NCT07572864 ↗ |
| Modality | Vaccine | “A vaccine targeting the IMP3 antigen” NCT07572864 ↗ |
| Route | Subcutaneous | “Administered via subcutaneous injection.” NCT07572864 ↗ |